Levodopa and the progression of parkinson’s disease

New England Journal of Medicine

Volumn 351, Issue 24, 2004, Pages 2498-2508

  Fahn, S ^a   Oakes, D ^an   Shoulson, I ^an   Kieburtz, K ^b   Rudolph, A ^c   Marek, K ^an   Seibyl, J ^d   Lang, A ^e   Olanow, C W ^f   Tanner, C ^g   Schifitto, G ^c   Zhao, H ^c   Reyes, L ^a   Shinaman, A ^c   Comella, C ^h   Goetz, C ^h   Blasucci, L ^h   Samanta, J ⁱ   Stacy, M ⁱ   Williamson, K ⁱ   Harrigan, M ⁱ   Greene, P ^a   Ford, B ^a   Moskowitz, C ^a   Truong, D ^j   Pathak, M ^j   Jankovic, J ^k   Ondo, W ^k   Atassi, F ^k   Hunter, C ^k   Jacques, C ^l   Friedman, J H ^l   Lannon, M ^l   Russell, D S ^d   Jennings, D ^d   Fussell, B ^d   Standaert, D ^m   Schwarzschild, M A ^m   Growdon, J ^m   Tennis, M ^m   Gauthier, S ⁿ   Panisset, M ⁿ   Hall, J ⁿ   Gancher, S ^o   Hammerstad, J ^o   Stone, C ^o   Alexander Brown, B ^o   Factor, S ^p   Molho, E ^p   Brown, D ^p   Evans, S ^p   Clark, J ^q   Manyam, B ^q   Simpson, P ^q   Wulbrecht, B ^q   Whetteckey, J ^q   Martin, W ^r   Roberts, T ^r   King, P ^r   Hauser, R ^s   Zesiewicz, T ^s   Gauger, L ^s   Trugman, J ^t   Wooten, G F ^t   Rost Ruffner, E ^t   Perlmutter, J ^u   Racette, B ^u   Suchowersky, O ^v   Ranawaya, R ^v   Wood, S ^v   Pantella, C ^v   Kurlan, R ^c   Richard, I ^c   Pearson, N ^c   Caviness, J ^w   Adler, C ^w   Lind, M ^w   Simuni, T ^x   Siderowf, A ^x   Colcher, A ^x   Lloyd, M ^x   Weiner, W ^y   Shulman, L ^y   Koller, W ^y   Lyons, K ^y   Feldman, R ^z   St Hilaire, M H ^z   Ellias, S ^z   Thomas, C A ^z   Juncos, J ^aa   Watts, R ^aa   Partlow, A ^aa   Tetrud, J ^g   Togasaki, D M ^g   Welsh, M ^g,ai   Stewart, T ^g   Mark, M H ^ab   Sage, J I ^ab   Caputo, D ^ab   Gould, H ^ac   Rao, J ^ac   McKendrick, A ^ac   Brin, M ^f   Danisi, F ^f   Benabou, R ^f   Hubble, J ^ad   Paulson, G ^ad   Reider, C ^ad   Birnbaum, A ^e   Miyasaki, J ^e   Johnston, L ^e   So, J ^e   Pahwa, R ^ae   Dubinsky, R ^ae   Wszolek, Z ^af   Uitti, R ^af   Turk, M ^af   Tuite, P ^ag   Rottenberg, D ^ag   Hansen, J ^ag   Serrano Ramos, C ^ah   Waters, C ^ai   Lew, M ^ai   Kawai, C ^ai   O'Brien C ^aj   Kumar, R ^aj   Seeberger, L ^aj   Judd, D ^aj   Mendis, T ^ak   Barclay, C L ^ak   Grimes, D A ^ak   Sutherland, L ^ak   Dawson, T ^al   Reich, S ^al   Dunlop, R ^al   Albin, R ^am   Frey, K ^am   Wernette, K ^am   more..

^a Howard Hughes Medical Institute   (United States)

^b Clinical Trials Coordination Center   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g PARKINSON S INSTITUTE   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ BARROW NEUROLOGICAL INSTITUTE   (United States)

^j The Parkinson and Movement Disorders Institute   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l BROWN UNIVERSITY   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ MCGILL UNIVERSITY   (Canada)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p ALBANY MEDICAL COLLEGE   (United States)

^q TEXAS A AND M UNIVERSITY   (United States)

^r UNIVERSITY OF ALBERTA   (Canada)

^s UNIVERSITY OF SOUTH FLORIDA   (United States)

^t UNIVERSITY OF VIRGINIA   (United States)

^u WASHINGTON UNIVERSITY   (United States)

^v UNIVERSITY OF CALGARY   (Canada)

^w MAYO CLINIC   (United States)

^x UNIVERSITY OF PENNSYLVANIA   (United States)

^y UNIVERSITY OF MIAMI   (United States)

^z BOSTON UNIVERSITY   (United States)

^aa EMORY UNIVERSITY   (United States)

^ab UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^ac LOUISIANA STATE UNIVERSITY   (United States)

^ad OHIO STATE UNIVERSITY   (United States)

^ae UNIVERSITY OF KANSAS   (United States)

^af MAYO CLINIC   (United States)

^ag Minneapolis Veterans Affairs Health Care System   (United States)

^ah UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^ai UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^aj Colorado Neurological Institute   (United States)

^ak UNIVERSITY OF OTTAWA   (Canada)

^al JOHNS HOPKINS UNIVERSITY   (United States)

^am UNIVERSITY OF MICHIGAN   (United States)

^an NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; IODINE 123; LEVODOPA; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTONIA; FALLING; FATIGUE; FEMALE; FRACTURE; GAIT DISORDER; HEADACHE; HUMAN; HYPERTENSION; HYPESTHESIA; INFECTION; INSOMNIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; NERVE DEGENERATION; NEUROIMAGING; PAIN; PARKINSON DISEASE; PERICARDITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SINUSITIS; SOMNOLENCE; THORAX PAIN; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 19744378296     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa033447     Document Type: Article

References (35)

1. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson’s disease: a detailed study of influential factors in human brain amine analysis. J Neural Transm 1976;38:277-301.
2. Practice parameters: initial therapy of Parkinson’s disease (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1993;43:1296-7.
3. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999;56:529-35.
4. Fahn S. Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs 1997;8:376-93.
5. Fahn S. Is levodopa toxic? Neurology 1996;47:Suppl 3:S184-S195.
6. Barzilai A, Melamed E, Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson’s disease? Cell Mol Neurobiol 2001;21:215-35.
7. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003;304:792-800.
8. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50:858-63.
9. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43:561-75.
10. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl (3) nigrostriatal lesions. Mov Disord 2001;16:424-34.
11. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-8.
12. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-8.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
14. Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson’s disease. Vol. 2. Florham Park, N.J.: Macmillan Healthcare Information, 1987:153-163, 293-304.
15. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276: 374-9.
16. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson’s disease. Mov Disord 2000;15:485-9.
17. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995;38:771-7.
18. Marek K, Innis R, van Dyck C, et al. [123I]b-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001;57:2089-94.
19. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328:176-83.
20. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I ]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995;38: 589-98.
21. Marek K, Seibyl J, Parkinson Study Group. b-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: longterm imaging assessment. Neurology 2003; 60:Suppl 1:A298. abstract.
22. Hauser RA, Holford NHG. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson’s disease. Mov Disord 2002;17:961-8.
23. Muenter MD, Tyce GM. L-dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-9.
24. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine trans-porter in early PD. Neurology 2001;56:1559-64.
25. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287: 1653-61.
26. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999;14:436-42.
27. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [F-18]CFT PET study. J Cereb Blood Flow Metab 2000;20:1604-9.
28. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993; 61:1470-8.
29. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de Yebenes J. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 1997;104:317-28.
30. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-408.
31. Desagher S, Glowinski J, Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996;16:2553-62.
32. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-10.
33. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985;254:2792-5.
34. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord 2001;16:960-2.
35. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REALPET study. Ann Neurol 2003;54:93-101.